Literature DB >> 19211762

Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination.

Fu Shi Quan1, Dae-Goon Yoo, Jae-Min Song, John D Clements, Richard W Compans, Sang-Moo Kang.   

Abstract

The format of influenza virus-like particles (VLPs) as a nonreplicating particulate vaccine candidate is a promising alternative to conventional egg-based vaccines. In this study, we have investigated the detailed kinetics of immune responses and protective efficacy after a single intranasal immunization with different doses of VLPs alone or in the presence of an Escherichia coli mutant heat-labile enterotoxin [mLT(R192G)] or cholera toxin subunit B as adjuvants. Analysis of immune responses showed differential kinetics in a VLP antigen dose-dependent manner and dynamic changes in the ratios of antibody immunoglobulin G isotypes over the time course. Protection against lethal challenge was observed with a single immunization with influenza VLPs even without adjuvant. The addition of adjuvant showed significant antigen-sparing effects with improved protective efficacy. The protective immune responses, efficacies of protection, and antigen-sparing effects were significantly improved by a second immunization as determined by the levels of neutralizing antibodies, morbidity postchallenge, lung viral titers, and inflammatory cytokines. Our results are informative for a better understanding of the protective immunity induced by a single dose or two doses of influenza VLPs, which is dependent on antigen dosage and the presence of adjuvant, and will provide insights into designing effective vaccines based on VLPs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211762      PMCID: PMC2668456          DOI: 10.1128/JVI.02035-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

Authors:  Ayato Takada; Sachiko Matsushita; Ai Ninomiya; Yoshihiro Kawaoka; Hiroshi Kida
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

2.  Gangliosides and membrane receptors for cholera toxin.

Authors:  P Cuatrecasas
Journal:  Biochemistry       Date:  1973-08-28       Impact factor: 3.162

3.  Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus.

Authors:  Z Sha; R W Compans
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans.

Authors:  M Jertborn; I Nordström; A Kilander; C Czerkinsky; J Holmgren
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

5.  Calcium signaling through phospholipase C activates dendritic cells to mature and is necessary for the activation and maturation of dendritic cells induced by diverse agonists.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; George K Lewis
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

6.  A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs.

Authors:  Fu Shi Quan; David Steinhauer; Chunzi Huang; Ted M Ross; Richard W Compans; Sang-Moo Kang
Journal:  Vaccine       Date:  2008-04-11       Impact factor: 3.641

7.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland.

Authors:  Margot Mutsch; Weigong Zhou; Philip Rhodes; Matthias Bopp; Robert T Chen; Thomas Linder; Christian Spyr; Robert Steffen
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

8.  Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.

Authors:  T M Tumpey; M Renshaw; J D Clements; J M Katz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells.

Authors:  Mimi Guebre-Xabier; Scott A Hammond; Diane E Epperson; Jianmei Yu; Larry Ellingsworth; Gregory M Glenn
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 10.  Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines.

Authors:  Samuele Peppoloni; Paolo Ruggiero; Mario Contorni; Maurizio Morandi; Mariagrazia Pizza; Rino Rappuoli; Audino Podda; Giuseppe Del Giudice
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

View more
  39 in total

1.  Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.

Authors:  Fu-Shi Quan; Yonghwan Kim; Sujin Lee; Hong Yi; Sang-Moo Kang; Jadranka Bozja; Martin L Moore; Richard W Compans
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

Review 2.  Progress in developing virus-like particle influenza vaccines.

Authors:  Fu-Shi Quan; Young-Tae Lee; Ki-Hye Kim; Min-Chul Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2016-05-05       Impact factor: 5.217

3.  Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination.

Authors:  Eunju O; Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Yu-Na Lee; Jae-Min Song; Young-Man Kwon; Min-Chul Kim; Daniel R Perez; Sang-Moo Kang
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

4.  Stability of influenza vaccine coated onto microneedles.

Authors:  Hyo-Jick Choi; Dae-Goon Yoo; Brian J Bondy; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  Biomaterials       Date:  2012-02-21       Impact factor: 12.479

5.  Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization.

Authors:  Fu-Shi Quan; Yeu-Chun Kim; Aswani Vunnava; Dae-Goon Yoo; Jae-Min Song; Mark R Prausnitz; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

Review 6.  Cutaneous immunization: an evolving paradigm in influenza vaccines.

Authors:  Harvinder S Gill; Sang-Moo Kang; Fu-Shi Quan; Richard W Compans
Journal:  Expert Opin Drug Deliv       Date:  2014-02-12       Impact factor: 6.648

7.  Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles.

Authors:  Yeu-Chun Kim; Fu-Shi Quan; Dae-Goon Yoo; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

8.  Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice.

Authors:  Fu-Shi Quan; Aswani Vunnava; Richard W Compans; Sang-Moo Kang
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

9.  Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines.

Authors:  Marc Pearton; Sang-Moo Kang; Jae-Min Song; Alexander V Anstey; Matthew Ivory; Richard W Compans; James C Birchall
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

10.  Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin.

Authors:  Fu-Shi Quan; Yeu-Chun Kim; Dae-Goon Yoo; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.